[SCHEDULE 13G] AETHLON MEDICAL INC SEC Filing

Rhea-AI Filing Summary

Aethlon Medical, Inc. reporting persons Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC filed a Schedule 13G disclosing potential and actual beneficial ownership related to a September 4, 2025 Securities Purchase Agreement. The filing explains that, before blocker provisions are applied, each reporting person could have been deemed to beneficially own 1,111,110 shares. As of the close of business on September 10, 2025, each reporting person is reported as beneficially owning 576,603 shares, representing approximately 7.7% of the common stock. The ownership includes 21,048 shares held by Intracoastal and 555,555 shares issuable upon exercise of a warrant, and the filing describes blocker provisions limiting exercise to prevent ownership above 9.99%.

Positive

• Transparent disclosure of beneficial ownership, including exact share counts and warrant details
• Inclusion of blocker provisions that clearly limit warrant exercise above 9.99%, reducing ambiguity about potential control shifts
• Joint Filing Agreement and certifications included and properly executed, supporting regulatory compliance

Negative

• Significant warrant exposure (555,555 shares issuable) creates potential dilution overhang, even though exercise is limited by blockers
• Shared voting power but no sole control indicates coordinated influence rather than clear single-party governance authority

Insights

Financial Analyst

TL;DR: Reporting group holds 7.7% post-transaction with material warrant exposure, constrained by 9.99% blocker provisions.

The Schedule 13G discloses a meaningful minority position in Aethlon Medical resulting from a Securities Purchase Agreement executed September 4, 2025. The group reports aggregate beneficial ownership of 576,603 shares (7.7%) as of September 10, 2025, including a large tranche of warrants (555,555 shares issuable) and a smaller direct holding (21,048 shares). The filing clearly documents blocker provisions that cap exercise rights to avoid exceeding 9.99%, which materially affects potential dilution and near-term conversion dynamics. The disclosure is precise and compliant, enabling investors to quantify the groups stake and warrant-related overhang.

Corporate Governance Expert

TL;DR: The filing shows shared voting/dispositive power without sole control and includes required certifications and a joint filing agreement.

The report indicates shared voting power of 576,603 shares and shared dispositive power of 555,555 shares, with no sole voting or dispositive power recorded. Signatures from both individuals and Intracoastals manager accompany the filing and the exhibit list includes a Joint Filing Agreement, demonstrating coordinated disclosure. The certification affirms the securities were not acquired to change control. These elements speak to proper governance disclosure and clarify that the position is a collective, not unilateral, control attempt.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Aethlon Medical, Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

00808Y505

(CUSIP Number)

09/04/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 00808Y505

1

Names of Reporting Persons

Mitchell P. Kopin

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 576,603.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 555,555.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

576,603.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

7.7 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

CUSIP No. 00808Y505

1

Names of Reporting Persons

Daniel B. Asher

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 576,603.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 555,555.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

576,603.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

7.7 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

CUSIP No. 00808Y505

1

Names of Reporting Persons

Intracoastal Capital LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 576,603.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 555,555.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

576,603.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

7.7 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Aethlon Medical, Inc.
(b)	Address of issuer's principal executive offices: 11555 Sorrento Valley Road, Suite 203, San Diego, California 92121
Item 2.
(a)	Name of person filing: This Schedule 13G is being filed on behalf of (i) Mitchell P. Kopin, an individual ("Mr. Kopin"), (ii) Daniel B. Asher, an individual ("Mr. Asher") and (iii) Intracoastal Capital LLC, a Delaware limited liability company ("Intracoastal" and together with Mr. Kopin and Mr. Asher, collectively the "Reporting Persons").
(b)	Address or principal business office or, if none, residence: The principal business office of Mr. Kopin and Intracoastal is 245 Palm Trail, Delray Beach, Florida 33483. The principal business office of Mr. Asher is 1011 Lake Street, Suite 311, Oak Park, Illinois 60301.
(c)	Citizenship: Mr. Kopin is a citizen of the United States of America. Mr. Asher is a citizen of the United States of America. Intracoastal is a Delaware limited liability company.
(d)	Title of class of securities: Common Stock, par value $0.001 per share
(e)	CUSIP No.: 00808Y505
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: (i) Immediately following the execution of the Securities Purchase Agreement with the Issuer on September 4, 2025 (the "SPA") (as disclosed in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on September 9, 2025), each of the Reporting Persons may have been deemed to have beneficial ownership of 288,424 shares of Common Stock, which consisted of (i) 280,000 shares of Common Stock to be issued to Intracoastal at the closing of the transaction contemplated by the SPA and (ii) 8,424 shares of Common Stock issuable upon exercise of a warrant to be issued to Intracoastal at the closing of the transaction contemplated by the SPA ("Intracoastal Warrant 1"), and all such shares of Common Stock represent beneficial ownership of approximately 9.99% of the Common Stock, based on (1) 2,598,711 shares of Common Stock outstanding as of September 3, 2025, as reported by the Issuer, plus (2) 280,000 shares of Common Stock to be issued to Intracoastal at the closing of the transaction contemplated by the SPA and (3) 8,424 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1. The foregoing excludes (I) 267,131 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1 because Intracoastal Warrant 1 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 1 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 9.99% of the Common Stock and (II) 555,555 shares of Common Stock issuable upon exercise of a second warrant to be issued to Intracoastal at the closing of the transaction contemplated by the SPA ("Intracoastal Warrant 2") because Intracoastal Warrant 2 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 2 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 9.99% of the Common Stock. Without such blocker provisions, each of the Reporting Persons may have been deemed to have beneficial ownership of 1,111,110 shares of Common Stock. (ii) As of the close of business on September 10, 2025, each of the Reporting Persons may have been deemed to have beneficial ownership of 576,603 shares of Common Stock, which consisted of (i) 21,048 shares of Common Stock held by Intracoastal and (ii) 555,555 shares of Common Stock issuable upon exercise of Intracoastal Warrant 2, and all such shares of Common Stock represent beneficial ownership of approximately 7.7% of the Common Stock, based on (1) 2,598,711 shares of Common Stock outstanding as of September 3, 2025, as reported by the Issuer, plus (2) 4,047,780 shares of Common Stock issued at the closing of the transaction contemplated by the SPA, (3) 275,555 shares of Common Stock issued to Intracoastal upon exercise of Intracoastal Warrant 1 and (4) 555,555 shares of Common Stock issuable upon exercise of Intracoastal Warrant 2.
(b)	Percent of class: 7.7%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 576,603
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 555,555
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Mitchell P. Kopin

Signature:	/s/ Mitchell P. Kopin
Name/Title:	Mitchell P. Kopin
Date:	09/10/2025

Daniel B. Asher

Signature:	/s/ Daniel B. Asher
Name/Title:	Daniel B. Asher
Date:	09/10/2025

Intracoastal Capital LLC

Signature:	/s/ Mitchell P. Kopin
Name/Title:	Mitchell P. Kopin, Manager
Date:	09/10/2025

Exhibit Information

Exhibit 1 - Joint Filing Agreement

FAQ

How many AEMD shares do the reporting persons beneficially own?

As of the close of business on September 10, 2025, each reporting person is reported as beneficially owning 576,603 shares, representing 7.7% of the common stock.

What transaction prompted this Schedule 13G filing for AEMD?

The filing follows a Securities Purchase Agreement executed on September 4, 2025, as disclosed by the issuer in a separate filing.

Do the reporting persons have voting control of the shares?

The filing reports 0 sole voting power and 576,603 shared voting power, indicating shared voting authority rather than sole control.

Are there warrants included in the reported ownership for AEMD?

Yes. The reported ownership includes 555,555 shares issuable upon exercise of Intracoastal Warrant 2 and earlier references to Intracoastal Warrant 1.

What limits exist on exercising warrants disclosed in the filing?

Both warrants described contain a blocker provision preventing exercise to the extent such exercise would result in beneficial ownership exceeding 9.99% of the common stock.